4.55
-0.03(-0.66%)
Currency In USD
| Previous Close | 4.58 |
| Open | 4.58 |
| Day High | 4.65 |
| Day Low | 4.45 |
| 52-Week High | 12.4 |
| 52-Week Low | 3.5 |
| Volume | 206,223 |
| Average Volume | 452,561 |
| Market Cap | 281.01M |
| PE | 11.67 |
| EPS | 0.39 |
| Moving Average 50 Days | 4.97 |
| Moving Average 200 Days | 5.97 |
| Change | -0.03 |
If you invested $1000 in Monte Rosa Therapeutics, Inc. (GLUE) since IPO date, it would be worth $214.83 as of August 18, 2025 at a share price of $4.55. Whereas If you bought $1000 worth of Monte Rosa Therapeutics, Inc. (GLUE) shares 3 years ago, it would be worth $499.45 as of August 18, 2025 at a share price of $4.55.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Monte Rosa Therapeutics Announces First Subjects Dosed in Phase 1 Study of MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases
GlobeNewswire Inc.
Jul 21, 2025 11:00 AM GMT
MRT-8102 Phase 1 study includes single and multiple ascending dose cohorts in healthy volunteers and is designed to evaluate safety, pharmacokinetics, NEK7 protein degradation, and other key downstream pharmacodynamic markers; initial results anticip
Monte Rosa Announces Publication in Science of Key Insights that Enable Next Generation Molecular Glue Degrader Medicines
GlobeNewswire Inc.
Jul 03, 2025 6:15 PM GMT
Monte Rosa’s AI/ML-powered insights dramatically increase targetable protein space for molecular glue degraders, unlocking new opportunities to address previously undruggable therapeutic targets Science, 3 July 2025 Molecular Glue Computational min
Monte Rosa Therapeutics Announces FDA Clearance of IND Application for MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases
GlobeNewswire Inc.
Jun 10, 2025 11:00 AM GMT
MRT-8102, a highly selective NEK7-directed molecular glue degrader (MGD) developed to treat inflammatory conditions linked to NLRP3, IL-1β, and IL-6 dysregulation, expands Monte Rosa’s clinical I&I portfolio Potency, selectivity, and long-lasting pha